Home » The Viewpoint » Page 25

Category Archives: The Viewpoint

Ops Page for Editorials, and …Opinions

Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs

Posted on by — No Comments ↓

Several interesting articles appeared recently which shed light on the efficacy of eravacycline and the safety of omadacycline, both in Phase 3 and both in a head-to-head race to the market.  Well, the term ‘race’ is bit of a stretch as both drugs have seen very significant delays in development. Omadacycline from Continue reading Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs→

The EpiPen Episode, an Epitaph on Epinephrine as we know it, an Epilogue and an Epiphany

Posted on by — No Comments ↓

For a good long time, economists have been thinking about the reimbursement quandary for antibiotics, esp. antibacterials. They are just too cheap, right?  Well, with the exception of HCV and some newer HIV drugs, few compounds have ever reached the stratospheric prices that oncology drugs or TNF alpha inhibitors command. Continue reading The EpiPen Episode, an Epitaph on Epinephrine as we know it, an Epilogue and an Epiphany→

Choose your Outcome: How Design Minutiae Affect Trial Results

Posted on by — No Comments ↓

When you search for ‘ceftidoren’ on Wikipedia, you will get a surprise: there is no entry. However, a search on the web tells us that Spectracef (ceftidoren pivoxil) still exists. Gee, now the drug is spelled ‘cefditoren’ and – looking through the list of retrieved articles – it seems that Continue reading Choose your Outcome: How Design Minutiae Affect Trial Results→